World desk · Wed 28 Oct 2026 · 34 stories from 14 countries
Peptide Global follows medicines such as semaglutide, tirzepatide and insulin one market at a time: who approved what, where copies launch as patents end, which plants open and which deals cross borders. Five regional desks file every story under the country it happened in. How we file
Desk 01 · 10 stories
Open the Americas deskBRBrazilMarket
Torrent Pharmaceuticals told investors it expects to launch generic semaglutide in Brazil within six to nine months, after Brazil sales rose 38 percent in the September quarter.
Desk 02 · 8 stories
Open the Europe deskCHSwitzerlandMoney
PolyPeptide shareholders elected a five member board chaired by Samsung Biologics CEO John Rim and removed transfer and voting limits, both effective only at settlement of the CHF 44.31 per share offer.
Desk 03 · 2 stories
Open the Middle East and Africa deskETEthiopiaMoney
Kilitch sells 100% of its Ethiopian cephalosporin unit to an Oromia state enterprise for $14 million, $12.855 million of it to Kilitch, to fund debt cuts and a phased Pen site with GLP-1 plans.
Desk 04 · 10 stories
Open the Asia-Pacific deskKRSouth KoreaResearch
Daewon Pharmaceutical says its oral semaglutide candidate DW5324 reached 1.90 to 3.14 times the exposure of Rybelsus in two crossover studies of 18 and 19 people, presented at AAPS PharmSci 360.
Desk 05 · 4 stories
Open the Across borders deskXBAcross bordersMakingExplainer
Catalent's head of global product development described how lipid based softgels with immediate release or enteric shells protect oral peptides, ahead of the AAPS PharmSci 360 meeting.